Bolivia Medical Device Registration: Certificate Ownership under Section 3.2.1
Updated: 2026-11-12 · GRZAN Regulatory Team · Verification date 2026-10-20
1. Key takeaways
Section 3.2.1 of the Manual para Registro Sanitario de Dispositivos Médicos is the most consequential passage in the Bolivian system for a foreign manufacturer. It states explicitly that the registration certificate is not necessarily owned by the company that filed the registration, but by the holder of the product licence or its manufacturer. At the same time, the entity that holds the certificate in day-to-day administrative reality remains the Bolivian importer: the company that holds the operating licence, signs Form 027 and appears on the face of the dossier. GRZAN’s assessment is that this constitutes a gap between the rule and the practice: the legal text gives the manufacturer a basis for a claim of ownership, while the name printed on the file is the importer’s. That gap can only be bridged by contract; it will not resolve itself through the rule.
The consequence is a specific and predictable kind of exposure. The registration certificate is the asset that carries commercial value in the Bolivian market, and the party that can renew it, amend it, transfer it or decline to do any of those things is not the party that commissioned the work. When a distribution relationship deteriorates, the manufacturer discovers that its access to the market is held through a document that another company controls administratively, even where the same document describes the product as the manufacturer’s. Ownership on paper and control in practice are two different questions in Bolivia, and they are answered by two different instruments.
The practical conclusion is therefore narrow and actionable: treat section 3.2.1 as a negotiating asset at the point of signature, not as a remedy available afterwards. Everything that protects the manufacturer has to be written into the distribution agreement before the first dossier is filed, and it has to be written by someone who has read both the manual and Bolivian contract law.
2. Legal basis
| Regulatory instrument | Number | Publication date | Relevant provisions |
|---|---|---|---|
| Manual para Registro Sanitario de Dispositivos Médicos | Resolución Ministerial N° 010 | As per the current version on the AGEMED website | Section 3.2.1 |
| Manual para Registro Sanitario de Dispositivos Médicos | Resolución Ministerial N° 010 | As per the current version on the AGEMED website | Section 2.1 |
| Manual para Registro Sanitario de Dispositivos Médicos | Resolución Ministerial N° 010 | As per the current version on the AGEMED website | Section 2.2.1 |
| Decreto Supremo (implementing regulation of the medicines law) | Decreto Supremo N° 25235 | 30 November 1998 | Article 42 |
The four provisions work as a chain rather than as alternatives. Section 3.2.1 supplies the ownership principle; sections 2.1 and 2.2.1 fix who may appear as the applicant of record and what that applicant must demonstrate about its establishment; Article 42 of Decreto Supremo N° 25235 requires the importing enterprise to register with the Ministry of Health the legal representation conferred on it by the manufacturing plant, stating the period of validity. Read together, they explain why the manual can assign ownership to the manufacturer while the file itself carries the importer’s name: the manual governs the product licence, the decree governs the legal representation of the manufacturer, and the dossier sits at the intersection of the two.
3. Expert insights
Insight 1: section 3.2.1 is a negotiating starting point, not a safeguard. What the section supplies is not the outcome that the certificate automatically belongs to the manufacturer, but a rule-based position that can be cited. What actually determines the outcome is the ownership clause and the transfer mechanism in the distribution agreement. GRZAN’s recommendation is to have the wording of section 3.2.1 written verbatim into the recitals of the agreement, so that the manufacturer’s claim rests on a document the counterparty has already accepted, rather than on an argument raised for the first time during a dispute.
Insight 2: a fragmented holder base weakens the leverage of replacing a partner. On a practical estimate (third-party counts of the official AGEMED weekly bulletin), the 74 weekly bulletins issued between January 2025 and June 2026 list approximately 3,800 distinct applicants, and the leading importers account for only about 1% to 3% of them. This means that replacing an uncooperative importer in Bolivia is harder than in neighbouring markets: substitutes are numerous, but none of them has a scale advantage sufficient to absorb national distribution. Leverage has to be built at signature; it cannot be assumed to exist after a relationship breaks down.
Insight 3: ownership, transfer and cooperation must be drafted as one package. A clause stating that the registration belongs to the manufacturer is not enough on its own. GRZAN’s standard drafting is three parallel clauses: an ownership clause, an on-demand transfer clause under which the registration is transferred to a party designated by the manufacturer when the manufacturer so requires, and a change-cooperation clause obliging the importer to complete any procedure required to change the holder. The three only work as a set, because each one depends on the next: ownership without transfer is a statement of intent, and transfer without cooperation is a right that cannot be exercised.
Insight 4: the administrative file, not the certificate, is where control actually sits. Every subsequent action on a Bolivian registration passes through the applicant of record: renewal, variation of the manufacturing site list, labelling changes, responses to deficiency letters. A manufacturer that holds a contractual right of ownership but depends on a reluctant counterparty to sign each of those actions holds a right it cannot use. This is why the cooperation clause deserves at least as much drafting attention as the ownership clause, and why it should carry defined response times and defined consequences for delay.
4. Practical recommendations
- Cite section 3.2.1 of the manual verbatim in the recitals of the distribution agreement, so that the ownership claim rests on an accepted text.
- Write both the on-demand transfer obligation and the change-cooperation obligation into the agreement, and attach defined consequences to breach of each.
- Have the agreement reviewed by a Bolivian lawyer before the first submission. This is the one point on which GRZAN does not compromise in Bolivian projects.
- Keep a documentary record of the manufacturer’s role in the product, such as the licence relationship and the manufacturing site authorisation, so that the ownership position can be evidenced and not merely asserted.
5. Verification checklist
- □ The distribution agreement states that registration ownership rests with the manufacturer or the holder of the product licence
- □ A clause providing for transfer to a designated party at the manufacturer’s request is included
- □ The importer’s obligation to cooperate with holder changes is included
- □ The agreement has been reviewed by a Bolivian lawyer
- □ The ownership position under section 3.2.1 has been expressly communicated to the importer
Regulatory information verified as of October 29, 2026.
GRZAN supports medical device manufacturers, importers and authorised representatives with registration in Bolivia, including the drafting and review of ownership, transfer and change-cooperation clauses against section 3.2.1 of Resolución Ministerial N° 010 and Article 42 of Decreto Supremo N° 25235, the preparation of representation filings with AGEMED, and the coordination of holder changes once a registration is in force. For assistance with a specific product or contract in Bolivia, contact the GRZAN regulatory team at info@grzanglobal.com.
GRZAN maintains a standing practice of conclusions first, traceable sources and verifiable figures in all of its regulatory writing, and tracks changes at AGEMED and the other authorities cited in this series as they are published. For a market access plan covering the ownership structure, the dossier and the post-registration maintenance of a Bolivian registration, the team welcomes your enquiry.
Disclaimer
Prepared by GRZAN from publicly available regulation. It is provided for general information only and does not constitute legal advice. Legislation and official fees are subject to change by the competent authority.
About GRZAN
GRZAN (Global Regulatory Zone Access Navigator) — the global market-access navigator for medical devices and IVDs.
GRZAN is a specialist consultancy for medical device and IVD market access, providing end-to-end regulatory solutions across the product lifecycle and making international market entry simpler and faster.
Key figures. More than 25 wholly owned subsidiaries worldwide covering 50+ countries and regions; chosen by 100+ listed and leading Chinese device manufacturers, with 4,000+ successful cases; 12+ years in the sector and 200+ regulatory training sessions and seminars delivered.
What we do. Global market access: multi-country registration programmes, technical documentation, regulatory advice. Clinical evidence: clinical evaluation reports (CER), usability studies, overseas clinical investigations. Quality systems: ISO 13485, MDSAP, FDA QMSR and BGMP implementation and audit readiness. Authorised representative and licence-holder services across Southeast Asia, Latin America, the Middle East, Africa, Europe and North America.
Why GRZAN. A real operating entity, with the certificate held by the manufacturer: our direct overseas subsidiaries act as the compliant local holder, so the regulatory relationship stays clear and you keep control rather than being tied to a distributor. Direct access to the team: no time-zone gap, no language barrier, no cultural gap. Review points anticipated: we know what FDA 510(k), EU MDR, Southeast Asian, Latin American and Middle Eastern reviewers look for, which shortens timelines and reduces deficiency letters. Pathway planning: pre-decision analysis and risk assessment before you commit.
Every engagement rests on three commitments: efficiency through pre-submission review, certainty through a clear pathway, and stability through a licence-holder that stays in place.
Take your devices global with GRZAN
We work with manufacturers worldwide to open new markets with a clear regulatory pathway.
Contact us